Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaF PET/CT to Assess Orteronel Response in mCRPC
NCT01816048Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orteronel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Wisconsin–Madison. Started May 2013; status: terminated.
02
Drugs
orteronel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01816048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01816048.